SIDEBAR: Timing of Prostate Cancer Drugs: Earlier But Not Too Early?


Get Permission

While sipuleucel-T, abiraterone, and cabazitaxel have been approved for patients with advanced disease, they might also be used in patients with earlier-stage disease, according to Christopher J. Logothetis, MD, of MD Anderson Cancer Center. “I think it is fair to say that they will be used better and more efficiently in a select group of patients early in the disease. There are already trials using abiraterone in the preoperative setting before radical prostatectomy and they show promise in what appears to be an enhanced effect on the tumor,” he reported.

“The unique problem with prostate cancer is that ‘earlier therapy’ can sometimes be too early,” Dr. Logothetis said. “If patients are only exposed to the drugs for 5 years, the side effects may be modest, but if patients live for an entire decade or more, continued exposure to therapy may be significantly more toxic. The goal is to offer therapies after the cancer has demonstrated its potential to get aggressive, but before the cancer is visibly causing problems. To do this, we need to develop better biomarkers that identify the transition to an aggressive cancer before it becomes obvious clinically,” he said ■


Related Articles

Optimizing Treatment for Advanced Prostate Cancer Requires Shifting Focus from Individual Drugs to Integrated Therapies

Newer drugs, including sipuleucel-T (Provenge), cabazitaxel (Jevtana), and abiraterone (Zytiga), can extend survival modestly and ease symptoms for men with advanced prostate cancer. Maximizing the benefit to patients will require shifting the focus from developing individual drugs to developing...

SIDEBAR: Expect Questions from Your Patients

Drugs for the treatment of prostate cancer have been in the news because of recent approvals by the FDA, the costs connected with their use, and associated improvements in survival.1 More recently reported was the decision to allow Medicare coverage of sipuleucel-T treatment for men who met the FDA ...


Advertisement

Advertisement



Advertisement